Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022 16:01 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 19, 2022 16:01 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
September 14, 2022 20:07 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
In der HARMONY-Studie der Phase 2b von Akero Therapeutics wurde in der 50-mg- und der 28-mg-EFX-Dosisgruppe nach 24 Wochen statistische Signifikanz bei primären und sekundären histologischen Endpunkten erzielt
September 14, 2022 07:18 ET
|
Akero Therapeutics
In den Gruppen mit 50 mg (41 %) und 28 mg (39 %) wurde im Vergleich zu Placebo (20 %) eine doppelt so hohe Anzahl von Patienten mit mindestens einstufiger Verbesserung der Fibrose ohne...
Dans l'étude HARMONY de phase 2b d'Akero Therapeutics, les doses de 50 mg et 28 mg d'EFX ont atteint la signification statistique sur les critères d'évaluation histologique primaires et secondaires après 24 semaines
September 14, 2022 07:18 ET
|
Akero Therapeutics
Les groupes recevant 50 mg (41 %) et 28 mg (39 %) ont affiché une amélioration d'au moins 1 stade de la fibrose sans aggravation de la NASH, le double par rapport au placebo (20 %) Les groupes...
Akero Therapeutics Announces Proposed Public Offering of Common Stock
September 13, 2022 16:01 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
September 13, 2022 06:00 ET
|
Akero Therapeutics
50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution...
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
September 08, 2022 16:01 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
August 24, 2022 08:00 ET
|
Akero Therapeutics
33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent with the results for the pre-cirrhotic population (F1-F3),...
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022 16:05 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...